Product image of Iskidrop (Nimodipine) supplied by GNH India

Iskidrop

Active Ingredient:
Nimodipine
Origin:
EU

Iskidrop (Nimodipine)

Nimodipine, the active ingredient in Iskidrop, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to prevent cerebral vasospasm in patients who have experienced a subarachnoid hemorrhage. By selectively targeting L‑type calcium channels in cerebral vessels, it helps maintain adequate blood flow during the critical post‑hemorrhage period.

GNH India supplies Iskidrop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation to support global distribution.

Manufacturer / TM Owner

Neopharmed Gentili Spa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

Nimodipine is a cerebral vasodilator used in the management of vascular complications following subarachnoid hemorrhage.

  • Subarachnoid hemorrhage (SAH): prevention of cerebral vasospasm after SAH.
  • Cerebral vasospasm: reduction of vasospasm severity in patients with SAH.
  • Neurosurgical procedures: prophylactic vasodilation to support cerebral perfusion during postoperative recovery.

How It Works

  • Nimodipine acts as an L‑type calcium channel antagonist with preferential activity in cerebral arteries. By blocking calcium influx into vascular smooth‑muscle cells, it induces relaxation of cerebral vessels, lowering vascular resistance and improving cerebral blood flow. This selectivity helps limit systemic hypotension while targeting the cascade that leads to vasospasm after subarachnoid hemorrhage.

Side Effects

Nimodipine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate.
  • Dizziness or light‑headedness.
  • Nausea or vomiting.
  • Flushing or warmth sensation.
  • Hypotension: transient blood pressure drop.
  • Peripheral edema: mild swelling of ankles.

Serious or Rare Side Effects

  • Severe hypotension: marked blood pressure reduction.
  • Cardiac arrhythmias: irregular heart rhythm.
  • Hepatotoxicity: elevated liver enzymes.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Thrombocytopenia: low platelet count.

Precautions & Warnings

When prescribing Nimodipine, clinicians should consider several safety measures to minimize risk.

  • Cardiovascular monitoring: observe blood pressure and heart rate during initiation.
  • Hepatic function: assess liver enzymes before and during therapy.
  • Concomitant vasodilators: avoid simultaneous use with other potent vasodilators.
  • Renal impairment: adjust use in patients with severe renal dysfunction.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Avoid Interactions

Nimodipine can alter the pharmacokinetics or pharmacodynamics of several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nimodipine plasma levels.
  • Simultaneous use with other calcium channel blockers: risk of additive hypotension.
  • Nitrates: excessive vasodilation leading to severe hypotension.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
  • Beta‑blockers: may enhance bradycardia.
  • Diuretics: may potentiate blood pressure lowering.
  • Anticoagulants: monitor for increased bleeding risk due to hypotension‑related falls.

Frequently Asked Questions

Iskidrop contains Nimodipine, which is indicated to prevent cerebral vasospasm in patients who have suffered a subarachnoid hemorrhage. By maintaining adequate cerebral blood flow, it helps reduce the risk of delayed ischemic neurological deficits that can follow the bleed.

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This inhibition reduces calcium entry, causing the vessels to relax and dilate, which improves cerebral perfusion and counteracts the vasospasm that often develops after subarachnoid hemorrhage.

The dose of Iskidrop is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Healthcare professionals follow local prescribing guidelines to set the appropriate regimen.

Safety data for Nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Iskidrop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective vasodilators, Nimodipine offers greater affinity for cerebral vessels, providing targeted vasodilation with less systemic hypotension. This selectivity makes it a preferred option for managing vasospasm after subarachnoid hemorrhage, whereas other agents may lack this cerebral specificity.

Iskidrop should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly closed and keep it out of reach of children.

Iskidrop is administered orally, typically as a solution or tablet taken with water. The exact method—such as taking it with or without food—depends on the prescriber’s instructions and the patient’s tolerance.

Serious risks include severe hypotension, cardiac arrhythmias, hepatotoxicity, and rare allergic reactions such as anaphylaxis. Patients should be monitored for sudden drops in blood pressure, irregular heartbeats, or signs of liver dysfunction, and any concerning symptoms should be reported promptly.

Iskidrop is contraindicated in patients with known hypersensitivity to Nimodipine or other calcium channel blockers. Caution is also advised for individuals with severe hypotension, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nimodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT